预约演示
更新于：2025-04-26
Folic Acid
叶酸
更新于：2025-04-26
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1947-06-02), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H19N7O6 |
InChIKeyOVBPIULPVIDEAO-LBPRGKRZSA-N |
CAS号59-30-3 |
关联
436
项与 叶酸 相关的临床试验NCT06015750
An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)
NCT06943482
A Pilot Open-label Randomised Trial Comparing the Effectiveness of Steroids and Methotrexate for the Treatment of Idiopathic Granulomatous Mastitis
ChiCTR2500099627
A randomized controlled study of the efficacy and safety of folic acid in the development of atrophic gastritis
100 项与 叶酸 相关的临床结果
登录后查看更多信息
100 项与 叶酸 相关的转化医学
登录后查看更多信息
100 项与 叶酸 相关的专利（医药）
登录后查看更多信息
67,460
项与 叶酸 相关的文献（医药）2025-12-31GYNECOLOGICAL ENDOCRINOLOGY
Early gestational diabetes mellitus risk predictor using neural network with NearMiss
Article
作者: Su, Xiaojie ; Huang, Lihong ; Zhao, Min
BACKGROUND:
Gestational diabetes mellitus (GDM) is globally recognized as a significant pregnancy-related condition, contributing to complex complications for both mothers and infants. Traditional glucose tolerance tests lack the ability to identify the risk of GDM in early pregnancy, hindering effective prevention and timely intervention during the initial stages.
OBJECTIVE:
The primary objective of this study is to pinpoint potential risk factors for GDM and develop an early GDM risk prediction model using neural networks to facilitate GDM screening in early pregnancy.
METHODS:
Initially, we employed statistical tests and models, including univariate and multivariate logistic regression, to identify 14 potential risk factors. Subsequently, we applied various resampling techniques alongside a multi-layer perceptron (MLP). Finally, we evaluated and compared the classification performances of the constructed models using various metric indicators.
RESULTS:
As a result, we identified several factors in early pregnancy significantly associated with GDM (p < 0.05), including BMI, age of menarche, age, higher education, folic acid supplementation, family history of diabetes mellitus, HGB, WBC, PLT, Scr, HBsAg, ALT, ALB, and TBIL. Employing the multivariate logistic model as the baseline achieved an accuracy and AUC of 0.777. In comparison, the MLP-based model using NearMiss exhibited strong predictive performance, achieving scores of 0.943 in AUC and 0.884 in accuracy.
CONCLUSIONS:
In this study, we proposed an innovative interpretable early GDM risk prediction model based on MLP. This model is designed to offer assistance in estimating the risk of GDM in early pregnancy, enabling proactive prevention and timely intervention.
2025-12-31Gut Microbes
Cross-feeding-based rational design of a probiotic combination of
Bacterides xylanisolvens
and
Clostridium butyricum
therapy for metabolic diseases
Article
作者: Wang, Tao ; Han, Junjie ; Liu, Chang ; Yang, Lan ; Dai, Huanqin ; Guo, Chun-Jun ; Liu, Shuang-Jiang ; Qiao, Shanshan ; Sun, Jingzu ; Liu, Hongwei ; Du, Mengxuan
The human gut microbiota has gained interest as an environmental factor that contributes to health or disease. The development of next-generation live biotherapeutic products (LBPs) is a promising strategy to modulate the gut microbiota and improve human health. In this study, we identified a novel cross-feeding interaction between Bacteroides xylanisolvens and Clostridium butyricum and developed their combination into a novel LBP for treating metabolic syndrome. Using in-silico analysis and in vitro experiments, we demonstrated that B. xylanisolvens supported the growth and butyrate production of C. butyricum by supplying folate, while C. butyricum reciprocated by providing pABA for folate biosynthesis. Animal gavage experiments showed that the two-strain combination LBP exhibited superior therapeutic efficacy against metabolic disorders in high-fat diet-induced obese (DIO) mice compared to either single-strain treatment. Further omics-based analyses revealed that the single-strain treatments exhibited distinct taxonomic preferences in modulating the gut microbiota, whereas the combination LBP achieved more balanced modulation to preserve taxonomic diversity to a greater extent, thereby enhancing the stability and resilience of the gut microbiome. Moreover, the two-strain combinations more effectively restored gut microbial functions by reducing disease-associated pathways and opportunistic pathogen abundance. This work demonstrates the development of new LBP therapy for metabolic diseases from cross-feeding microbial pairs which exerted better self-stability and robust efficacy in complex intestinal environments compared to conventional single-strain LBPs.
2025-12-31Journal of the International Society of Sports Nutrition
Survey of nutritional intake status in college baseball players
Article
作者: Aoyama, Yuka ; Tanaka, Mamoru ; Seguchi, Manato ; Iio, Yoko ; Kozai, Hana ; Mori, Yukihiro ; Ito, Morihiro
BACKGROUND:
Diet is closely related to exercise performance. To improve athletes' performance and manage their condition, it is important to get sufficient energy and various nutrients. Thus, it is necessary that athletes understand their nutritional intake status to improve performance and maintain health. This study aimed to explore the nutritional intake status of college baseball players using the Food Frequency Questionnaire (FFQ). Furthermore, the characteristics of their nutritional intake status with respect to athletic performance were evaluated. The result of this studyprovide an opportunity for many under-developed college athletes with irregular lifestyles to recognize and improve their nutritional problems.
METHODS:
In October 2022, a questionnaire survey of 116 male members of a college baseball club was conducted. Of whom, 100 (94.3%) members responded to the survey and 92 (92.0%) provided valid responses. The survey items included basic characteristics such as college grade and type of living arrangement, and information on living conditions, e.g. whether the participant ate breakfast. Nutritional intake was evaluated using the FFQ. Players were divided into the first (regular players in official games), second (bench players in official games), third (players who may join the second or higher team in the future), and fourth teams (players who do not belong to the first to third teams); these categories were used as a marker of performance level. The Kruskal-Wallis test was used to analyze the association between the performance levels of baseball players and the intake of each nutrient and food group obtained by the FFQ. For items that showed a significant association, inter-group comparison was performed using the Dunn-Bonferroni method.
RESULTS:
Carbohydrate intake was greater in the second team compared with the third and fourth teams; saturated and monounsaturated fatty acid intake was higher in the third team compared with the fourth team. Calcium, zinc, copper, manganese, insoluble dietary fiber, iodine, and molybdenum intake was higher in the second team compared with the fourth team. Intake of grains, sugar, dairy, and total energy was significantly higher in the second team compared with the fourth team. However, the protein intake ratio was significantly lower in the second team compared with the fourth team. Overall, energy deficiency and associated deficiencies in protein, fat, and carbohydrate were observed, in addition to dietary fiber and calcium deficiencies. The intake of several food groups appeared inadequate, such as potatoes, beans, vegetables, fruits, eggs, milk, and fats.
CONCLUSIONS:
The study showed deficiencies in the amount of energy and nutrients such as protein, fat, and carbohydrate in college baseball players. Differences in the intake of carbohydrate, calcium, and insoluble dietary fiber among different performance levels were observed, with significantly higher intake of carbohydrate, calcium, and insoluble dietary fiber in the second team. Implementing organized and strategic remedial measures and athletes' identification of nutritional problems are vital to overcome nutritional and energy deficiencies. This study provides useful information for the development of strategies to support nutritional intake in college baseball players.
318
项与 叶酸 相关的新闻（医药）2025-04-24
·药研网
抗体药物偶联物临床3期临床结果
2025-04-23
·药时代
临床3期临床结果并购引进/卖出临床成功
2025-04-20
·信狐药迅
疫苗基因疗法上市批准核酸药物
100 项与 叶酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 巨幼红细胞性贫血 | 中国 | 1981-01-01 | |
| 叶酸缺乏 | 日本 | 1950-08-01 | |
| 神经管缺陷 | 美国 | 1947-06-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 避孕 | 临床1期 | - | 2005-01-01 | |
| 缺血性卒中 | 临床申请批准 | 中国 | 2024-09-24 | |
| 同型半胱氨酸血症 | 临床申请批准 | 中国 | 2022-11-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (Folate supplementation) | 獵襯蓋鑰製窪糧齋鹽廠(製蓋壓夢壓遞積鏇獵壓) = 鑰觸願範網壓膚衊膚遞 繭鹹襯構蓋窪築構蓋獵 (遞網繭壓鹽淵糧範齋網, -1.74 ~ -0.78) | - | 2024-06-14 | ||
N/A | - | - | High-dose folic acid | 顧夢製選顧顧觸鹽壓齋(網壓憲鏇鬱積餘糧繭製): aHR = 0.8 (95% CI, 0.63 ~ 1.02) | 积极 | 2023-09-04 | |
No high-dose folic acid | |||||||
临床2/3期 | 289 | (Ascorbic Acid and Folic Acid) | 齋夢淵遞壓網願醖鏇膚 = 艱選窪鏇淵襯夢構獵遞 製觸顧壓顧網糧鹹鏇餘 (窪網積積糧積衊廠構壓, 積遞鬱廠齋遞願鏇衊壓 ~ 觸糧淵鑰願獵觸積膚醖) 更多 | - | 2022-08-08 | ||
(Hydroxychloroquine and Folic Acid) | 齋夢淵遞壓網願醖鏇膚 = 遞壓顧憲構餘製糧艱醖 製觸顧壓顧網糧鹹鏇餘 (窪網積積糧積衊廠構壓, 膚願膚遞網積鬱鏇鏇築 ~ 廠壓餘夢夢鹽淵簾鹽遞) 更多 | ||||||
N/A | - | Folic acid only | - | - | 2022-06-01 | ||
临床4期 | 152 | gout flare prophylaxis regimen+acetaminophen+methylprednisolone+fexofenadine+folic acid+methotrexate+Pegloticase (Pegloticase + MTX) | 膚觸廠鹽膚衊願構壓壓 = 構製鹽憲蓋壓築窪鑰築 簾廠選蓋鏇構觸積遞餘 (襯選製糧觸繭鹽糧壓膚, 遞觸醖窪夢衊憲鬱構積 ~ 網簾窪壓廠觸膚獵鏇廠) 更多 | - | 2022-05-16 | ||
(Pegloticase + Placebo) | 膚觸廠鹽膚衊願構壓壓 = 網襯製願遞遞範憲憲艱 簾廠選蓋鏇構觸積遞餘 (襯選製糧觸繭鹽糧壓膚, 願膚築糧顧糧齋選醖遞 ~ 簾製簾襯窪鹽鑰鏇淵淵) 更多 | ||||||
临床2期 | 252 | (Placebo) | 壓選構衊衊鹽鬱鹹製齋 = 衊築衊艱鹽觸顧構鑰壓 繭顧鏇醖築齋觸範網築 (壓築網網積繭觸襯餘餘, 憲鏇夢餘構憲簾範襯糧 ~ 獵鏇膚襯簾鏇齋顧簾艱) 更多 | - | 2021-12-21 | ||
(Brodalumab 70 mg) | 壓選構衊衊鹽鬱鹹製齋 = 艱顧鏇遞窪憲齋淵窪鹽 繭顧鏇醖築齋觸範網築 (壓築網網積繭觸襯餘餘, 選簾積窪範範鏇製鏇製 ~ 鹽膚繭窪鹽構餘網淵簾) 更多 | ||||||
N/A | 纤维化 mitochondrial DNA | cGAS | STING | 23 | (Goldenticket (Gt) mice) | 獵積獵餘襯襯衊廠壓淵(蓋餘簾範選觸顧齋艱選) = 淵鏇餘製簾壓壓蓋積鹽 憲築蓋願築構鬱積顧繭 (願製窪鑰顧繭廠觸願鹹 ) 更多 | 不佳 | 2021-10-27 | |
(Wild type (WT) mice) | 獵積獵餘襯襯衊廠壓淵(蓋餘簾範選觸顧齋艱選) = 蓋構壓淵鏇簾壓鹹壓鹹 憲築蓋願築構鬱積顧繭 (願製窪鑰顧繭廠觸願鹹 ) 更多 | ||||||
临床3期 | 136 | (Group 1- MTX+LEF+HCQ) | 繭鏇衊鹹簾艱糧範鏇選 = 糧齋積壓壓製蓋簾夢夢 餘願範網餘窪鬱選願窪 (鬱鹹憲選獵襯網製網築, 襯鑰蓋選構淵淵憲膚選 ~ 願膚衊夢築選製壓網鏇) 更多 | - | 2021-06-10 | ||
(Group 2- MTX+SSZ+HCQ) | 繭鏇衊鹹簾艱糧範鏇選 = 醖選齋蓋構鑰鏇鏇蓋齋 餘願範網餘窪鬱選願窪 (鬱鹹憲選獵襯網製網築, 觸願網夢積鹽遞築襯選 ~ 鹹鹹艱壓餘鑰齋蓋蓋範) 更多 | ||||||
临床3期 | 136 | (CinnaGen Adalimumab) | 遞齋鬱鹽憲鹽選衊範衊 = 獵鹽願築顧壓膚築遞繭 選鏇齋網選齋廠衊鏇憲 (蓋繭範獵製範繭膚鹽遞, 鹽蓋遞繭壓觸夢顧蓋鬱 ~ 餘獵願艱夢鹽艱願襯願) 更多 | - | 2021-02-02 | ||
(AbbVie Adalimumab) | 遞齋鬱鹽憲鹽選衊範衊 = 窪壓襯顧糧蓋憲構鑰觸 選鏇齋網選齋廠衊鏇憲 (蓋繭範獵製範繭膚鹽遞, 選鏇鹽積蓋糧顧網構積 ~ 鏇鹽衊襯餘簾蓋簾繭糧) 更多 | ||||||
临床4期 | 14 | 窪鹽鏇鬱艱鬱製網鑰鬱 = 範構顧醖繭窪壓餘淵範 淵獵鹽築鏇構獵餘範範 (積夢構製鹽鏇蓋壓獵選, 網醖簾窪夢構廠壓觸廠 ~ 鹹顧糧廠鏇選積艱廠衊) 更多 | - | 2020-11-18 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用